ANVS

ANNOVIS BIO, INC.

ANVS · CIK 1477845 · Annual (10-K) · Last 5 years

Financial Trends

Revenue$0M
20202024
Net Income−$25M
20202024
Operating CF−$22M
20202024
Free Cash Flow
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense—————
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$-0.0B$-0.1B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-2.02$-6.23$-3.10$-1.90—
EPS (Diluted)$-2.31$-6.23$-3.10$-1.90—

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.0B$0.0B$0.0B$0.0B$0.0B
Current Assets—$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$-0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow—————
Capital Expenditures—————
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.0B
← Companies